<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067129</url>
  </required_header>
  <id_info>
    <org_study_id>M16-123</org_study_id>
    <secondary_id>2016-004102-34</secondary_id>
    <nct_id>NCT03067129</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection</brief_title>
  <acronym>DORA</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics,&#xD;
      efficacy,and safety of glecaprevir (GLE)/pibrentasvir (PIB) for 8, 12, or 16 weeks in&#xD;
      Hepatitis C virus (HCV) genotype 1-6 (GT1 - GT6)-infected pediatric participants ≥ 3 to &lt; 18&#xD;
      years of age, with or without compensated cirrhosis, with or without human immunodeficiency&#xD;
      virus (HIV) coinfection, who were either treatment-naïve (TN), treatment-experienced (TE)&#xD;
      with pegylated interferon (pegIFN) with or without ribavirin (RBV), or TE with sofosbuvir&#xD;
      (SOF) + RBV with or without pegIFN. The study was divided into 2 parts, according to the&#xD;
      formulation of GLE/PIB administered. Part 1 of the study enrolled HCV GT1 - GT6 infected&#xD;
      adolescent participants into the ≥ 12 to &lt; 18 years old age group who were willing to swallow&#xD;
      the adult formulation of GLE/PIB (Cohort 1). Part 2 of the study enrolled HCV GT1 - GT6&#xD;
      infected pediatric participants divided into the ≥ 9 to &lt; 12 (Cohort 2), ≥ 6 to &lt; 9 (Cohort&#xD;
      3), and ≥ 3 to &lt; 6 (Cohort 4) years old age groups, who received the pediatric formulation of&#xD;
      GLE + PIB.&#xD;
&#xD;
      Interim data are presented for all participants in Parts 1 and 2 who completed post-treatment&#xD;
      Week 12 or prematurely discontinued from the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">November 21, 2022</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-state Area Under the Plasma Concentration-time Curve (AUC) of Glecaprevir (GLE) at Week 2</measure>
    <time_frame>At Week 2</time_frame>
    <description>AUC is a measure of how long and how much drug is present in the body after dosing. The amount of glecaprevir present was measured up to 24 hours after dosing and estimated using non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state Area Under the Plasma Concentration-time Curve (AUC) of Pibrentasvir (PIB) at Week 2</measure>
    <time_frame>At Week 2</time_frame>
    <description>AUC is a measure of how long and how much drug is present in the body after dosing. The amount of pibrentasvir present was measured up to 24 hours after dosing and estimated using non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)</measure>
    <time_frame>12 weeks after last dose of study drug (Week 20, 24, or 28 depending on treatment duration)</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) &lt; lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Glecaprevir (GLE) at Week 2</measure>
    <time_frame>At Week 2</time_frame>
    <description>Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose. It was estimated by non-compartmental pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Glecaprevir (GLE) From Plasma at Week 2</measure>
    <time_frame>At Week 2</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Pibrentasvir (PIB) at Week 2</measure>
    <time_frame>At Week 2</time_frame>
    <description>Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose. It was estimated by non-compartmental pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Pibrentasvir (PIB) From Plasma at Week 2</measure>
    <time_frame>At Week 2</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced On-treatment Virologic Failure</measure>
    <time_frame>Up to Week 8, 12, or 16 (depending on treatment duration)</time_frame>
    <description>On-treatment virologic failure is defined as hepatitis C virus ribonucleic acid (HCV RNA) confirmed increase of &gt; 1 (subscript)10(subscript) IU/mL above nadir during treatment, confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; lower limit of quantification (LLOQ) during treatment, or HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-treatment Relapse</measure>
    <time_frame>Up to 12 weeks after the last dose of study drug (Week 20, 24, or 28 depending on treatment duration)</time_frame>
    <description>Post-treatment relapse is defined as confirmed hepatitis C virus ribonucleic acid (HCV RNA) ≥ the lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA &lt; LLOQ at the end of treatment; excluding participants who had been shown to be re-infected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Hepatitis C Virus (HCV) Infection (i.e., Reinfection)</measure>
    <time_frame>Up to 12 weeks after last dose of study drug (Week 20, 24, or 28 depending on treatment duration)</time_frame>
    <description>Reinfection is defined as confirmed hepatitis C virus ribonucleic acid (HCV RNA) ≥ the lower limit of quantification (LLOQ) in the post-treatment period along with post-treatment detection of a different HCV genotype, subtype, or clade compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability Questionnaire Question 1: How Convenient or Inconvenient Was it to Prepare the Dose?</measure>
    <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
    <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability Questionnaire Question 2: How Long Did it Typically Take for the Child to Take the Dose?</measure>
    <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
    <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability Questionnaire Question 3: Were You Able to Successfully Administer the Whole Dose to the Child With 1 to 2 Teaspoons (5 to 10 mL) of Soft Food?</measure>
    <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
    <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability Questionnaire Question 4: Did You Experience Any Resistance When Feeding the Child the Medicine?</measure>
    <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
    <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability Questionnaire Question 4a: Type of Feeding Resistance</measure>
    <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
    <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability Questionnaire Question 5: How Easy or Difficult Was it for the Child to Swallow the Medicine?</measure>
    <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
    <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Adult formulation GLE/PIB, participants 12 to &lt; 18 yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Pediatric formulation GLE/PIB, participants 9 to &lt; 12 yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Pediatric formulation GLE/PIB, participants 6 to &lt; 9 yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Pediatric formulation GLE/PIB, participants 3 to &lt; 6 yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/pibrentasvir adult formulation</intervention_name>
    <description>Film-coated tablet (100 mg/40 mg)</description>
    <arm_group_label>Cohort 1: Adult formulation GLE/PIB, participants 12 to &lt; 18 yrs</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/pibrentasvir pediatric formulation</intervention_name>
    <description>Film-coated pellets/granules (15.67%/8.25%)</description>
    <arm_group_label>Cohort 2: Pediatric formulation GLE/PIB, participants 9 to &lt; 12 yrs</arm_group_label>
    <arm_group_label>Cohort 3: Pediatric formulation GLE/PIB, participants 6 to &lt; 9 yrs</arm_group_label>
    <arm_group_label>Cohort 4: Pediatric formulation GLE/PIB, participants 3 to &lt; 6 yrs</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Hepatitis C virus (HCV) infection demonstrated by positive anti-HCV antibody (Ab) and HCV&#xD;
        Ribonucleic acid (RNA) greater than or equal to 1000 IU/ mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Positive test result for Hepatitis B surface antigen (HbsAg) or positive test result&#xD;
             for HBV DNA&#xD;
&#xD;
          -  Participants with other known liver diseases&#xD;
&#xD;
          -  Decompensated cirrhosis defined as: presence of ascites, history of variceal bleeding,&#xD;
             lab values consistent with Child-Pugh class B or C cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of California San Francis /ID# 158002</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Colorado /ID# 157996</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CT Childrens Medical Ctr, US /ID# 158639</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Hepatology Research at CTRB /ID# 158008</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Health /ID# 166022</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University /ID# 158001</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital /ID# 157988</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center /ID# 157997</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center /ID# 158000</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Health Care /ID# 157991</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hosp Med /ID# 158007</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia /ID# 158003</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Hosp of Pittsburgh,PA /ID# 158004</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe-Carell Jr. Children's H /ID# 169037</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine /ID# 157989</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 162173</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 162174</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital /ID# 163449</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital /ID# 163450</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children /ID# 163448</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg /ID# 165187</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin /ID# 165186</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal /ID# 165185</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital /ID# 165718</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center /ID# 212745</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital /ID# 165709</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital /ID# 212912</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children Hospital /ID# 160850</name>
      <address>
        <city>San Juan</city>
        <zip>00912-3310</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution - Institute of Nutrition /ID# 163345</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Scientific Centre of children health /ID# 163344</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119296</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific and Research Institute of pediatric infections /ID# 163343</name>
      <address>
        <city>Saint-petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu /ID# 163282</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron /ID# 163323</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 163283</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe /ID# 163325</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Childrens Hospital /ID# 162718</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hos /ID# 162719</name>
      <address>
        <city>Glasgow</city>
        <zip>G514TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS /ID# 162717</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <results_first_submitted>May 14, 2021</results_first_submitted>
  <results_first_submitted_qc>June 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C Virus</keyword>
  <keyword>Glecaprevir</keyword>
  <keyword>Pibrentasvir</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Treatment naïve</keyword>
  <keyword>Treatment experienced</keyword>
  <keyword>Interferon (IFN)</keyword>
  <keyword>Pegylated interferon (pegIFN)</keyword>
  <keyword>Ribavirin (RBV)</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Non-cirrhotic cirrhosis</keyword>
  <keyword>Compensated (Child-Pugh A) cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03067129/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03067129/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Safety population: all participants who received at least 1 dose of study drug</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
          <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Partially dosed; refused to swallow entire dose</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT population): all participants who received at least 1 dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
          <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.26" spread="1.51"/>
                    <measurement group_id="B2" value="10.00" spread="0.85"/>
                    <measurement group_id="B3" value="7.11" spread="0.89"/>
                    <measurement group_id="B4" value="3.79" spread="0.78"/>
                    <measurement group_id="B5" value="9.79" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Fibrosis Stage</title>
          <description>Fibrosis stage was determined by biopsy score, FibroScan score (if biopsy not available), or FibroTest score (if biopsy and FibroScan not available) and is equivalent to the liver biopsy Metavir score: F0-F1 (0 or 1), F2 (2), F3 (3), F4 (4). F0 indicates no signs of fibrosis and F4 indicates presence of cirrhosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>F0-F1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Co-infection with Human Immunodeficiency Virus (HIV)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady-state Area Under the Plasma Concentration-time Curve (AUC) of Glecaprevir (GLE) at Week 2</title>
        <description>AUC is a measure of how long and how much drug is present in the body after dosing. The amount of glecaprevir present was measured up to 24 hours after dosing and estimated using non-compartmental analysis.</description>
        <time_frame>At Week 2</time_frame>
        <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Area Under the Plasma Concentration-time Curve (AUC) of Glecaprevir (GLE) at Week 2</title>
          <description>AUC is a measure of how long and how much drug is present in the body after dosing. The amount of glecaprevir present was measured up to 24 hours after dosing and estimated using non-compartmental analysis.</description>
          <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4790" lower_limit="3520" upper_limit="6500"/>
                    <measurement group_id="O2" value="7870" lower_limit="4140" upper_limit="14900"/>
                    <measurement group_id="O3" value="6860" lower_limit="4080" upper_limit="11500"/>
                    <measurement group_id="O4" value="7520" lower_limit="3870" upper_limit="14600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady-state Area Under the Plasma Concentration-time Curve (AUC) of Pibrentasvir (PIB) at Week 2</title>
        <description>AUC is a measure of how long and how much drug is present in the body after dosing. The amount of pibrentasvir present was measured up to 24 hours after dosing and estimated using non-compartmental analysis.</description>
        <time_frame>At Week 2</time_frame>
        <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Area Under the Plasma Concentration-time Curve (AUC) of Pibrentasvir (PIB) at Week 2</title>
          <description>AUC is a measure of how long and how much drug is present in the body after dosing. The amount of pibrentasvir present was measured up to 24 hours after dosing and estimated using non-compartmental analysis.</description>
          <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
          <units>ng•h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1380" lower_limit="1150" upper_limit="1660"/>
                    <measurement group_id="O2" value="2200" lower_limit="1460" upper_limit="3310"/>
                    <measurement group_id="O3" value="1640" lower_limit="1230" upper_limit="2190"/>
                    <measurement group_id="O4" value="1790" lower_limit="1350" upper_limit="2370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)</title>
        <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) &lt; lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.</description>
        <time_frame>12 weeks after last dose of study drug (Week 20, 24, or 28 depending on treatment duration)</time_frame>
        <population>Intention-to-treat (ITT population): all participants who received at least 1 dose of study drug; those with missing data after backwards imputation were counted as nonresponders</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O5">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
          <group group_id="O6">
            <title>Participants in Cohorts 1, 2, 3, and 4</title>
            <description>Participants who received at least 1 dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)</title>
          <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) &lt; lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.</description>
          <population>Intention-to-treat (ITT population): all participants who received at least 1 dose of study drug; those with missing data after backwards imputation were counted as nonresponders</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="92.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="93.1" lower_limit="78.0" upper_limit="98.1"/>
                    <measurement group_id="O3" value="100" lower_limit="87.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="95.8" lower_limit="79.8" upper_limit="99.3"/>
                    <measurement group_id="O5" value="96.3" lower_limit="89.5" upper_limit="98.7"/>
                    <measurement group_id="O6" value="97.6" lower_limit="93.3" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Glecaprevir (GLE) at Week 2</title>
        <description>Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose. It was estimated by non-compartmental pharmacokinetic analysis.</description>
        <time_frame>At Week 2</time_frame>
        <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Glecaprevir (GLE) at Week 2</title>
          <description>Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose. It was estimated by non-compartmental pharmacokinetic analysis.</description>
          <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1040" lower_limit="733" upper_limit="1480"/>
                    <measurement group_id="O2" value="1370" lower_limit="773" upper_limit="2440"/>
                    <measurement group_id="O3" value="1600" lower_limit="926" upper_limit="2770"/>
                    <measurement group_id="O4" value="1530" lower_limit="711" upper_limit="3290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL) of Glecaprevir (GLE) From Plasma at Week 2</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.</description>
        <time_frame>At Week 2</time_frame>
        <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) of Glecaprevir (GLE) From Plasma at Week 2</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.</description>
          <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6" lower_limit="46.1" upper_limit="85.1"/>
                    <measurement group_id="O2" value="31.8" lower_limit="16.7" upper_limit="60.3"/>
                    <measurement group_id="O3" value="29.1" lower_limit="17.3" upper_limit="49.0"/>
                    <measurement group_id="O4" value="19.9" lower_limit="10.2" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Pibrentasvir (PIB) at Week 2</title>
        <description>Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose. It was estimated by non-compartmental pharmacokinetic analysis.</description>
        <time_frame>At Week 2</time_frame>
        <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Pibrentasvir (PIB) at Week 2</title>
          <description>Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administered and before administration of a second dose. It was estimated by non-compartmental pharmacokinetic analysis.</description>
          <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="148" upper_limit="205"/>
                    <measurement group_id="O2" value="225" lower_limit="164" upper_limit="310"/>
                    <measurement group_id="O3" value="197" lower_limit="154" upper_limit="251"/>
                    <measurement group_id="O4" value="233" lower_limit="184" upper_limit="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL) of Pibrentasvir (PIB) From Plasma at Week 2</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.</description>
        <time_frame>At Week 2</time_frame>
        <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) of Pibrentasvir (PIB) From Plasma at Week 2</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. It was estimated by non-compartmental pharmacokinetic analysis.</description>
          <population>Part 1 participants with intensive pharmacokinetic (IPK) sampling in Part 1 (3 participants were excluded due to abnormally low values at the Week 2 visit) and Part 2 participants with IPK sampling in Part 2 following the final proposed dosing regimen (1 participant in Cohort 4 received 200/80 mg dose [weight &gt; 20kg] and was summarized in Cohort 3 based on actual dose received)</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" lower_limit="72.4" upper_limit="104"/>
                    <measurement group_id="O2" value="45.4" lower_limit="30.1" upper_limit="68.5"/>
                    <measurement group_id="O3" value="48.7" lower_limit="36.6" upper_limit="64.8"/>
                    <measurement group_id="O4" value="33.6" lower_limit="25.4" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced On-treatment Virologic Failure</title>
        <description>On-treatment virologic failure is defined as hepatitis C virus ribonucleic acid (HCV RNA) confirmed increase of &gt; 1 (subscript)10(subscript) IU/mL above nadir during treatment, confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; lower limit of quantification (LLOQ) during treatment, or HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment.</description>
        <time_frame>Up to Week 8, 12, or 16 (depending on treatment duration)</time_frame>
        <population>Intention-to-treat (ITT population): all participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O5">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
          <group group_id="O6">
            <title>Participants in Cohorts 1, 2, 3, and 4</title>
            <description>Participants who received at least 1 dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced On-treatment Virologic Failure</title>
          <description>On-treatment virologic failure is defined as hepatitis C virus ribonucleic acid (HCV RNA) confirmed increase of &gt; 1 (subscript)10(subscript) IU/mL above nadir during treatment, confirmed HCV RNA ≥ 100 IU/mL after HCV RNA &lt; lower limit of quantification (LLOQ) during treatment, or HCV RNA ≥ LLOQ at the end of treatment with at least 6 weeks of treatment.</description>
          <population>Intention-to-treat (ITT population): all participants who received at least 1 dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="13.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="4.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Post-treatment Relapse</title>
        <description>Post-treatment relapse is defined as confirmed hepatitis C virus ribonucleic acid (HCV RNA) ≥ the lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA &lt; LLOQ at the end of treatment; excluding participants who had been shown to be re-infected.</description>
        <time_frame>Up to 12 weeks after the last dose of study drug (Week 20, 24, or 28 depending on treatment duration)</time_frame>
        <population>Participants in ITT population with HCV RNA &lt; LLOQ at the final treatment visit who completed treatment (based on study drug duration) and had post-treatment HCV RNA data, excluding participants with HCV re-infection</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O5">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
          <group group_id="O6">
            <title>Participants in Cohorts 1, 2, 3, and 4</title>
            <description>Participants who received at least 1 dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Post-treatment Relapse</title>
          <description>Post-treatment relapse is defined as confirmed hepatitis C virus ribonucleic acid (HCV RNA) ≥ the lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA &lt; LLOQ at the end of treatment; excluding participants who had been shown to be re-infected.</description>
          <population>Participants in ITT population with HCV RNA &lt; LLOQ at the final treatment visit who completed treatment (based on study drug duration) and had post-treatment HCV RNA data, excluding participants with HCV re-infection</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.6"/>
                    <measurement group_id="O2" value="3.6" lower_limit="0.6" upper_limit="17.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="14.3"/>
                    <measurement group_id="O5" value="1.3" lower_limit="0.2" upper_limit="6.9"/>
                    <measurement group_id="O6" value="0.8" lower_limit="0.1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Hepatitis C Virus (HCV) Infection (i.e., Reinfection)</title>
        <description>Reinfection is defined as confirmed hepatitis C virus ribonucleic acid (HCV RNA) ≥ the lower limit of quantification (LLOQ) in the post-treatment period along with post-treatment detection of a different HCV genotype, subtype, or clade compared with baseline.</description>
        <time_frame>Up to 12 weeks after last dose of study drug (Week 20, 24, or 28 depending on treatment duration)</time_frame>
        <population>Intention-to-treat (ITT population): all participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
            <description>Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O5">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
          <group group_id="O6">
            <title>Participants in Cohorts 1, 2, 3, and 4</title>
            <description>Participants who received at least 1 dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Hepatitis C Virus (HCV) Infection (i.e., Reinfection)</title>
          <description>Reinfection is defined as confirmed hepatitis C virus ribonucleic acid (HCV RNA) ≥ the lower limit of quantification (LLOQ) in the post-treatment period along with post-treatment detection of a different HCV genotype, subtype, or clade compared with baseline.</description>
          <population>Intention-to-treat (ITT population): all participants who received at least 1 dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="80"/>
                <count group_id="O6" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="13.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="4.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palatability Questionnaire Question 1: How Convenient or Inconvenient Was it to Prepare the Dose?</title>
        <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
        <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
        <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Palatability Questionnaire Question 1: How Convenient or Inconvenient Was it to Prepare the Dose?</title>
          <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
          <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Borderline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very inconvenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palatability Questionnaire Question 2: How Long Did it Typically Take for the Child to Take the Dose?</title>
        <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
        <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
        <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Palatability Questionnaire Question 2: How Long Did it Typically Take for the Child to Take the Dose?</title>
          <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
          <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 to 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 to 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palatability Questionnaire Question 3: Were You Able to Successfully Administer the Whole Dose to the Child With 1 to 2 Teaspoons (5 to 10 mL) of Soft Food?</title>
        <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
        <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
        <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Palatability Questionnaire Question 3: Were You Able to Successfully Administer the Whole Dose to the Child With 1 to 2 Teaspoons (5 to 10 mL) of Soft Food?</title>
          <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
          <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palatability Questionnaire Question 4: Did You Experience Any Resistance When Feeding the Child the Medicine?</title>
        <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
        <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
        <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Palatability Questionnaire Question 4: Did You Experience Any Resistance When Feeding the Child the Medicine?</title>
          <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
          <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palatability Questionnaire Question 4a: Type of Feeding Resistance</title>
        <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
        <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
        <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data who answered &quot;Yes&quot; to question 4 of the Palatability Questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Palatability Questionnaire Question 4a: Type of Feeding Resistance</title>
          <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
          <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data who answered &quot;Yes&quot; to question 4 of the Palatability Questionnaire</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not like taste of medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like texture of medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like the soft food used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not like to swallow the amount of medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unrelated to the medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palatability Questionnaire Question 5: How Easy or Difficult Was it for the Child to Swallow the Medicine?</title>
        <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
        <time_frame>At the End of Treatment visit or at the premature discontinuation visit (up to 8, 12, or 16 weeks, depending on treatment duration)</time_frame>
        <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
            <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
          </group>
        </group_list>
        <measure>
          <title>Palatability Questionnaire Question 5: How Easy or Difficult Was it for the Child to Swallow the Medicine?</title>
          <description>For each participant who received the pediatric formulation (Cohorts 2 - 4), the parent(s)/guardian(s) completed a Palatability Questionnaire to provide feedback on the perception of the dosage form. The Palatability Questionnaire included 6 questions related to the administration and ingestion of the pediatric GLE/PIB formulation.</description>
          <population>Intention-to-treat population: participants who received at least one dose of the pediatric GLE/PIB formulation with available data</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Borderline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last study drug administration, up to 20 weeks. In addition, serious adverse events and protocol-related nonserious adverse events were collected from the time the participant signed the study-specific informed consent.</time_frame>
      <desc>TEAEs and SAEs are defined as any AE or SAE with onset or worsening reported by a participant from the time that the first dose of study drug is administered until 30 days have elapsed following discontinuation of study drug. TEAEs were collected whether elicited or spontaneously reported by the participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Adult Formulation GLE/PIB, Participants 12 to &lt; 18 Yrs</title>
          <description>Adult formulation glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: Pediatric Formulation GLE/PIB, Participants 9 to &lt; 12 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: Pediatric Formulation GLE/PIB, Participants 6 to &lt; 9 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 6 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age</description>
        </group>
        <group group_id="E5">
          <title>Cohorts 2- 4: Pediatric Formulation GLE/PIB, Participants 3 to &lt; 12 Yrs</title>
          <description>Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB) 15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 12 years of age</description>
        </group>
        <group group_id="E6">
          <title>Participants in Cohorts 1, 2, 3, and 4</title>
          <description>Participants who received at least 1 dose of study drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="80"/>
                <counts group_id="E6" subjects_affected="79" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>MOTION SICKNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E6" events="16" subjects_affected="16" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E6" events="13" subjects_affected="11" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>LICE INFESTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E6" events="18" subjects_affected="17" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E6" events="19" subjects_affected="15" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>INCREASED APPETITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E6" events="23" subjects_affected="19" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

